Key Takeaways CRISPR Therapeutics and Sirius start a phase II study of SRSD107 in thromboembolic disorders.SRSD107 targets Factor XI to prevent venous thromboembolism in knee arthroplasty patients.The collaboration expands CRISPR Therapeutics' pipeline into RNA therapeutics beyond gene therapies.CRISPR Therapeutics (CRSP) , along with privately held biotech, Sirius Therapeutics, announced the dosing of the first patient in a phase II study evaluating SRSD107, a next-generation, long-acting siRNA therapy for ...